159 related articles for article (PubMed ID: 12463579)
1. Thromboprophylaxis dosing: the relationship between timing of first administration, efficacy, and safety.
Kwong LM; Muntz JE
Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):16-20. PubMed ID: 12463579
[TBL] [Abstract][Full Text] [Related]
2. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
Bauer KA
Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
5. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Andersen JC
Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
7. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery.
Colwell CW; Kwong LM; Turpie AG; Davidson BL
J Arthroplasty; 2006 Jan; 21(1):36-45. PubMed ID: 16446183
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Turpie AG; Eriksson BI; Lassen MR; Bauer KA
J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
[TBL] [Abstract][Full Text] [Related]
9. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients.
Turpie AG; Lensing AW; Fuji T; Boyle DA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):114-21. PubMed ID: 19339838
[TBL] [Abstract][Full Text] [Related]
11. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
Bauer KA
Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
[TBL] [Abstract][Full Text] [Related]
13. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
Turpie AG; Eriksson BI; Bauer KA; Lassen MR
Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
Agnelli G; Haas S; Ginsberg JS; Krueger KA; Dmitrienko A; Brandt JT
J Thromb Haemost; 2007 Apr; 5(4):746-53. PubMed ID: 17408408
[TBL] [Abstract][Full Text] [Related]
16. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
[TBL] [Abstract][Full Text] [Related]
18. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
19. The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux?
Lalourcey L
Int J Clin Pract; 2003 May; 57(4):289-94. PubMed ID: 12800460
[TBL] [Abstract][Full Text] [Related]
20. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
Raskob GE; Hirsh J
Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
